Multiple myeloma · 14 regimens
Cost vs Efficacy · 5 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Thalidomide monotherapy Variant #03 | — | R 614 268 | 540d | ~23.0 mo | — | ~2 | ~R 1 228 537 PFS proxy · indirect | 1 |
Daratumumab monotherapy Variant #03 | — | R 366 888 | 28d | — | — | — | — | 1 |
Venetoclax monotherapy Variant #04 | — | R 163 252 | 28d | — | — | — | — | — |
Ixazomib monotherapy Variant #04 | — | R 57 453 | 28d | ~22.0 mo | — | ~24 | ~R 1 378 872 PFS proxy · indirect | 2 |
Vemurafenib monotherapy Variant #01 | — | R 13 464 | 28d | ~7.2 mo | ~15.5 mo | ~8 | ~R 107 711 PFS proxy · indirect | 4 |
Lenalidomide monotherapy N/A - secondary systemic drug | — | R 6 361 | 90d | ~41.0 mo | ~113.8 mo | ~14 | ~R 89 057 PFS proxy · indirect | 4 |
Carfilzomib monotherapy N/A - secondary systemic drug | — | R 434 | 28d | — | ~10.2 mo | — | — | 1 |
Pomalidomide monotherapy N/A - secondary systemic drug | — | R 0 | 28d | ~2.7 mo | — | ~3 | ~R 0 PFS proxy · indirect | 1 |
Talquetamab monotherapy Variant #01 Partial | — | — | 7d | — | — | — | — | — |
Teclistamab monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
Idecabtagene vicleucel monotherapy Variant #01 Partial | — | — | — | ~13.6 mo | — | — | — | 2 |
Ciltacabtagene autoleucel monotherapy Variant #01 Partial | — | — | — | — | — | — | — | 3 |
Elranatamab monotherapy Variant #01 Partial | — | — | 7d | — | — | — | — | — |
Daratumumab and hyaluronidase monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | 2 |
14 of 14 regimens shown